ArticleThe Journal of antimicrobial chemotherapy2019
Evaluation of apramycin against spectinomycin-resistant and -susceptible strains of Neisseria gonorrhoeae.
Article in The Journal of antimicrobial chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Global trends of antimicrobial resistance rates inFrontiers in pharmacology · 2024Pooled it
- Evidence for a Constrained Mutational Pathway to High-Level Spectinomycin Resistance inInternational journal of molecular sciences · 2026Article
- Membrane-Focused Strategies AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.The Lancet. Microbe · 2025Review
- Pulmonary Delivery of Antibiotics to the Lungs: Current State and Future Prospects.Pharmaceutics · 2025Review
- Effect of 13 traditional Chinese medicine drug preparations againstFrontiers in pharmacology · 2025Article
- In vitro susceptibility of Neisseria gonorrhoeae to netilmicin and etimicin in comparison to gentamicin and other aminoglycosides.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Article
- Potential of Natural Phenolic Compounds as Antimicrobial Agents against Multidrug-ResistantMolecules (Basel, Switzerland) · 2023Article
- Synthesis of 4-Tetrahedron · 2023Article
- Synthesis, Antibacterial and Antiribosomal Activity of the 3Antibiotics (Basel, Switzerland) · 2022Article
- Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose.The Journal of antimicrobial chemotherapy · 2022Article
- Structural and molecular rationale for the diversification of resistance mediated by the Antibiotic_NAT family.Communications biology · 2022Article
- Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics.Antibiotics (Basel, Switzerland) · 2021Review
- Review
- Translation error clusters induced by aminoglycoside antibiotics.Nature communications · 2021Article
- The Impact of Selected Bacterial Sexually Transmitted Diseases on Pregnancy and Female Fertility.International journal of molecular sciences · 2021Review
- Repurposing the Veterinary Antibiotic Apramycin for Antibacterial and Antibiofilm Activity AgainstFrontiers in microbiology · 2021Article
- Wild-type cutoff for Apramycin against Escherichia coli.BMC veterinary research · 2020Article
- Epidemiologic, Phenotypic, and Structural Characterization of Aminoglycoside-Resistance GeneInternational journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe emergence of Neisseria gonorrhoeae resistant to all currently available antimicrobial therapies poses a dire public health threat. New antimicrobial agents with activity against N. gonorrhoeae are urgently needed. Apramycin is an aminocyclitol aminoglycoside with broad-spectrum in vitro activity against MDR Gram-negative pathogens and Staphylococcus aureus. However, its activity against N. gonorrhoeae has not been described.
objectivesThe activity spectrum of apramycin against a collection of MDR N. gonorrhoeae was assessed. Isolates tested included those susceptible and resistant to the structurally distinct aminocyclitol, spectinomycin.
resultsThe modal MICs for apramycin and spectinomycin were 16 mg/L and 32 mg/L, respectively. The epidemiological cut-off (ECOFF) for apramycin was 64 mg/L. No strains among 77 tested had an MIC above this ECOFF, suggesting very low levels of acquired apramycin resistance. In time-kill analysis, apramycin demonstrated rapid bactericidal activity comparable to that of spectinomycin.
conclusionsApramycin has broad-spectrum, rapidly bactericidal activity against N. gonorrhoeae. Future pharmacokinetic and pharmacodynamic studies will be needed to determine whether apramycin and/or apramycin derivatives hold promise as new therapeutics for N. gonorrhoeae infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.